Home » Stocks » Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation (ADMP)

Stock Price: $1.14 USD -0.09 (-7.32%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $1.11 -0.03 (-2.63%) Aug 11, 7:58 PM

Stock Price Chart

Key Info

Market Cap 84.27M
Revenue (ttm) 21.87M
Net Income (ttm) -30.69M
Shares Out 73.92M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $1.14
Previous Close $1.23
Change ($) -0.09
Change (%) -7.32%
Day's Open 1.20
Day's Range 1.11 - 1.22
Day's Volume 3,736,916
52-Week Range 0.27 - 1.51

More Stats

Market Cap 84.27M
Enterprise Value 77.71M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 73.92M
Float 72.66M
EPS (basic) -0.51
EPS (diluted) -0.53
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.42M
Short Ratio 1.63
Short % of Float 6.17%
Beta 2.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.85
PB Ratio 2.74
Revenue 21.87M
Operating Income -30.67M
Net Income -30.69M
Free Cash Flow -17.33M
Net Cash 6.56M
Net Cash / Share 0.09
Gross Margin 28.86%
Operating Margin -140.23%
Profit Margin -140.30%
FCF Margin -79.22%
ROA -35.13%
ROE -84.10%
ROIC -209.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$1.25*
(9.65% upside)
Low
1.00
Current: $1.14
High
1.50
Target: 1.25
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520132012201120102009
Revenue22.1115.0913.076.47-----0.29
Revenue Growth46.58%15.4%101.94%-------
Gross Profit6.645.295.651.62-----0.03
Operating Income-29.35-39.46-24.69-25.20-13.85-4.40-3.22-4.82-6.24-3.98
Net Income-29.31-39.01-25.54-19.44-13.57-8.16-7.19-4.92-6.98-6.71
Shares Outstanding53.2639.0928.3517.5013.287.355.865.263.751.70
Earnings Per Share-0.55-1.00-0.90-1.19-1.03-1.22-1.23-1.02-1.87-3.91
Operating Cash Flow-19.89-32.66-15.13-21.16-10.34-6.78-2.56-3.35-4.31-2.00
Capital Expenditures-2.87-3.54-2.06-0.12--0.10----
Free Cash Flow-22.75-36.19-17.19-21.28-10.34-6.88-2.56-3.35-4.31-2.00
Cash & Equivalents8.8119.2718.335.104.085.400.000.011.240.29
Total Debt4.082.585.077.40-0.421.180.301.361.78
Net Cash / Debt4.7316.6913.27-2.304.084.98-1.18-0.29-0.12-1.49
Assets47.8458.3651.4037.7912.0615.120.350.171.730.68
Liabilities11.8011.6711.8612.512.752.934.682.893.114.95
Book Value36.0446.6939.5525.289.3112.19-4.33-2.72-1.38-4.27
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adamis Pharmaceuticals Corporation
Country United States
Employees 131
CEO Dennis J. Carlo

Stock Information

Ticker Symbol ADMP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Delivery
Unique Identifier NASDAQ: ADMP

Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.